GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors

Encouraging clinical results using immune checkpoint therapies to target the PD-1 axis in a variety of cancer types have paved the way for new immune therapy trials in brain tumor patients. However, the molecular mechanisms that regulate expression of the PD-1 pathway ligands, PD-L1 and PD-L2, remai...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Yujie, Liu, Connor J., Kobayashi, Dale K., Johanns, Tanner M., Bowman-Kirigin, Jay A., Schaettler, Maximilian O., Mao, Diane D., Bender, Diane, Kelley, Diane G., Uppaluri, Ravindra, Bi, Wenya Linda, Dunn, Ian F., Tao, Yu, Luo, Jingqin, Kim, Albert H., Dunn, Gavin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271235/
https://www.ncbi.nlm.nih.gov/pubmed/32493985
http://dx.doi.org/10.1038/s41598-020-65915-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271235/
https://www.ncbi.nlm.nih.gov/pubmed/32493985
http://dx.doi.org/10.1038/s41598-020-65915-z

Ejemplares similares